Accessibility Menu
Cencora logo

Cencora(NYSE) COR

Market Cap$63.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1995)+14,641%
5 Year+193%
1 Year+16%
1 Month+10%
$321.50
-3.71%
-12.38Today
Cencora last closing stock price
MetricPriceDate
Last closeUSD 333.872026-08-11
Cencora stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.01%USD 306.282026-08-04
1 month+10.03%USD 303.442026-07-10
3 month+30.88%USD 255.092026-05-13
Year to date-0.75%USD 336.402025-12-31
1 year+15.72%USD 288.522025-08-11
3 year+82.36%USD 183.082023-08-11
5 year+192.83%USD 114.012021-08-12
Since inception+14,641.48%USD 2.201995-04-04

Cencora Financials at a Glance

Market Cap

$63.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$332.77B

Net Income (TTM)

$2.62B

EPS (TTM)

$13.45

P/E Ratio

24.82

Dividend

$2.35

Beta (Volatility)

0.24 (Low)

Price

$321.50

Volume

330,655.277

Open

$319.59

Previous Close

$333.87

Daily Range

$316.03 - $323.59

52-Week Range

$244.82 - $377.54

Estimated Earnings Date

Nov 4, 2026

COR: Motley Fool Moneyball Superscore

70

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cencora

Cencora delivers medicines and healthcare products to hospitals, pharmacies, and clinics. Its services support both human and animal health providers worldwide.

What’s in the Box? Cencora’s Main Offerings

  • U.S. Healthcare Solutions (constituting approximately 90.6% of revenue for the nine months ended June 30, 2025): Distributes prescription drugs, over-the-counter products, and medical supplies to hospitals, pharmacies, and clinics.
  • Specialty Pharmaceuticals: Provides plasma, vaccines, and high-cost specialty drugs for complex conditions to healthcare providers.
  • Pharmacy Services: Offers pharmacy management, staffing, consulting, and supply management software to healthcare organizations.
  • Animal Health: Supplies medicines, vaccines, and diagnostics for pets and livestock to veterinarians and animal clinics.
  • International Healthcare Solutions (approximately 9% of revenue): Delivers pharmaceuticals and logistics services to pharmacies, hospitals, and health centers outside the U.S.

Growth Moves: Cencora’s Expansion Playbook

  • Acquired Retina Consultants of America in 2025, expanding specialty provider reach.
  • Integrated Alliance Healthcare and PharmaLex in recent years to boost international and consulting services.
  • Entered new global markets through Alliance Healthcare acquisition.
  • Invested in technology and distribution network upgrades since 2023 rebranding to Cencora.

Why Cencora Stands Out (Without the Hype)

Cencora’s global distribution network connects drug makers with healthcare providers efficiently. Its bundled services—like analytics and logistics—help clients manage costs and supply chains. The company’s scale supports reliable delivery and broad product access.

Five Things You Need to Know

  • Revenue was $85.93 billion in QQ1 2026, up 5.5% year-on-year.
  • Gross profit reached $3.07 billion in QQ1 2026, up 35.7% year-on-year.
  • Net income was $560 million in QQ1 2026, up 14.5% year-on-year.
  • Total debt rose to $8.24 billion as of June 30, 2025, mainly from acquisitions.

Bottom Line

Cencora has evolved through acquisitions and service diversification to support healthcare delivery worldwide. Its broad reach and bundled services help it adapt to changing industry needs.

AI Generated • Apr 16, 2026

Industry

Healthcare Providers and Services

Employees

51,000

CEO

Robert P. Mauch, PhD

Headquarters

Conshohocken, PA 19428-1800, US

COR Financials

Key Financial Metrics (TTM)

Gross Margin

3.71%

Operating Margin

1.30%

Net Income Margin

0.79%

Return on Equity

106.43%

Return on Capital

29.76%

Return on Assets

3.13%

Earnings Yield

4.03%

Dividend Yield

0.70%

Payout Ratio

17.83%

Stock Overview

Market Cap

$63.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

190.83M

Volume

330.66K

Avg. Volume

1.65M

Financials (TTM)

Gross Profit

$12.34B

Operating Income

$4.34B

EBITDA

$5.13B

Operating Cash Flow

$4.82B

Capital Expenditure

-$760.85M

Free Cash Flow

$4.06B

Cash & ST Invst.

$2.82B

Total Debt

$11.72B

Cencora Performance Analysis

Cencora annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30USD 238,587,006,00011.5%
20232023-09-30USD 262,173,411,0009.9%
20242024-09-30USD 293,958,599,00012.1%
20252025-09-30USD 321,332,819,0009.3%
Cencora sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-303.8%
Q12025-12-312.6%
Q22026-03-31-8.8%
Q32026-06-308.2%
Cencora annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30USD 8.048.9%
20232023-09-30USD 8.536.1%
20242024-09-30USD 7.53-11.7%
20252025-09-30USD 7.965.7%
Cencora sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-30-149.7%
Q12025-12-31264.0%
Q22026-03-31192.7%
Q32026-06-30-53.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$84.75B

+5.1%

Gross Profit

$3.61B

+35.7%

Gross Margin

4.26%

N/A

Market Cap

$63.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.30M

N/A

Employees

49,000

N/A

Net Income

$763.52M

+11.1%

EBITDA

$1.41B

+10.8%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$2.82B

+23.7%

Total Debt

$11.72B

+42.3%

Accounts Receivable

$25.45B

+3.6%

Inventory

$21.03B

+4.4%

Long Term Debt

$11.44B

+42.3%

Short Term Debt

$279.16M

+41.9%

Return on Assets

3.13%

N/A

Return on Invested Capital

17.62%

N/A

Free Cash Flow

$2.43B

+3382.5%

Operating Cash Flow

$2.65B

+2329.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BDXBecton, Dickinson and Company
$179.35-1.14%
PDCOPatterson Companies, Inc.
$31.33-0.90%
MLTOMEDirect Latino, Inc.
$0.00+0.00%
CVETCovetrus, Inc.
$20.99+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SMCISuper Micro Computer
$36.05+0.14%
INTCIntel
$100.58+0.03%
NOKNokia
$10.33+0.09%
CRWVCoreWeave
$108.18+0.20%

Questions About COR

What is the current price of Cencora?

Cencora is trading at $320.96 per share.

What is the 52-week range for Cencora?

Over the past 52 weeks, Cencora has traded between $244.82 and $377.54.

How much debt does Cencora have?

As of the most recent reporting period, Cencora reported total debt of $11.72B.

How much cash does Cencora have on hand?

Cencora reported $2.86B in cash and cash equivalents in its most recent financial results.

What is Cencora’s dividend yield?

Cencora currently has a dividend yield of 0.70%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.